The UK’s first patient was treated with an investigational drug for severe Covid-19-related lung disease, the Manchester University NHS Foundation Trust said Monday.
The patient is part of the Oscar study led by British pharmaceutical giant GlaxoSmithKline PLC, set up to investigate whether one of its pipelined drugs, Otilimab, can help reduce the effects of the so-called cytokine storm, a severe immune reaction in which the body begins to attack their own cells, which has been found in some hospitalized Covid-19 patients.
The drug is a monoclonal antibody that was already in advanced clinical trials and was originally regarded as a potential new treatment for rheumatoid arthritis.
The patient is being treated at Manchester Royal Infirmary, part of the Manchester University NHS Foundation Trust, and was recruited for the study on 1
The Oscar study, which stands for Otilimab in Severe Covid-19-Related Disease, is sponsored and funded by GlaxoSmithKline and is one of several studies that have received urgent public health research status from the UK Department of Health and Welfare. .
The study is expected to be rolled out to more hospitals across the UK, Manchester University NHS Foundation Trust said.
Write to Adriano Marchese at email@example.com